Hurd, Jason L.
Facile, Tiffany R.
Weiss, Jennifer
Hayes, Matthew
Hayes, Meredith
Furia, John P.
Maffulli, Nicola
Winnier, Glenn E.
Alt, Christopher
Schmitz, Christoph
Alt, Eckhard U.
Lundeen, Mark
Funding for this research was provided by:
Sanford Health (N/A)
InGeneron, Inc. (N/A)
Article History
Received: 7 January 2020
Accepted: 12 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: Ethical approval for this pilot study was granted by the Institutional Review Board of Sanford Health (Sanford IRB #3 registration number 00007985), and all subjects gave informed consent.
: We have obtained consent for publication.
: JLH, TRF, JW, MH, MH, and ML are employees of Sanford Health, a minority shareholder of InGeneron, Inc. (Houston, TX, USA), which is the manufacturer and distributor of the Transpose RT/Matrase system that was investigated in this pilot study. GEW is employed as Chief Scientific Officer at InGeneron, Inc. CS has served as consultant to SciCoTec (Gruenwald, Germany), the majority shareholder of InGeneron, Inc. CA is managing director of InGeneron GmbH (Munich, Germany) which is owned by InGeneron, Inc. EA is Executive Chair of InGeneron, Inc., and Chairman of the Board of SciCoTec.